国际眼科杂志
國際眼科雜誌
국제안과잡지
International Eye Science
2015年
11期
2009-2011
,共3页
老年性黄斑变性%息肉样脉络膜血管病变%康柏西普
老年性黃斑變性%息肉樣脈絡膜血管病變%康柏西普
노년성황반변성%식육양맥락막혈관병변%강백서보
age - related macular degeneration%polypoidal choroidal vasculopathy%conbercept
目的：：研究玻璃体腔注射康柏西普( Conbercept)治疗湿性老年性黄斑变性( wet age-related macular degeneration, wAMD)和息肉状脉络膜血管病变( polypoidal choroidal vasculopathy, PCV)的疗效。方法：临床确诊为wAMD患者16例16眼,确诊为PCV患者5例5眼纳入研究。所有患者常规行玻璃体腔注射康柏西普治疗,根据需要补充治疗。定期行最佳矫正视力和中央视网膜厚度、脉络膜厚度测量。结果：6mo时平均注射次数为2.93±0.27。基线及6mo时平均最佳矫正视力分别为0.87±0.52和0.74±0.43,差异无统计学意义。6 mo时视网膜中央厚度从352.24±131.82降至251.73±69.41μm(P<0.01),脉络膜厚度从331.93±115.35降至304.72±104.59μm(P<0.05)。结论：玻璃体腔注射康柏西普治疗wAMD及PCV可稳定视力,降低患眼视网膜厚度,具有良好的安全性。
目的：：研究玻璃體腔註射康柏西普( Conbercept)治療濕性老年性黃斑變性( wet age-related macular degeneration, wAMD)和息肉狀脈絡膜血管病變( polypoidal choroidal vasculopathy, PCV)的療效。方法：臨床確診為wAMD患者16例16眼,確診為PCV患者5例5眼納入研究。所有患者常規行玻璃體腔註射康柏西普治療,根據需要補充治療。定期行最佳矯正視力和中央視網膜厚度、脈絡膜厚度測量。結果：6mo時平均註射次數為2.93±0.27。基線及6mo時平均最佳矯正視力分彆為0.87±0.52和0.74±0.43,差異無統計學意義。6 mo時視網膜中央厚度從352.24±131.82降至251.73±69.41μm(P<0.01),脈絡膜厚度從331.93±115.35降至304.72±104.59μm(P<0.05)。結論：玻璃體腔註射康柏西普治療wAMD及PCV可穩定視力,降低患眼視網膜厚度,具有良好的安全性。
목적：：연구파리체강주사강백서보( Conbercept)치료습성노년성황반변성( wet age-related macular degeneration, wAMD)화식육상맥락막혈관병변( polypoidal choroidal vasculopathy, PCV)적료효。방법：림상학진위wAMD환자16례16안,학진위PCV환자5례5안납입연구。소유환자상규행파리체강주사강백서보치료,근거수요보충치료。정기행최가교정시력화중앙시망막후도、맥락막후도측량。결과：6mo시평균주사차수위2.93±0.27。기선급6mo시평균최가교정시력분별위0.87±0.52화0.74±0.43,차이무통계학의의。6 mo시시망막중앙후도종352.24±131.82강지251.73±69.41μm(P<0.01),맥락막후도종331.93±115.35강지304.72±104.59μm(P<0.05)。결론：파리체강주사강백서보치료wAMD급PCV가은정시력,강저환안시망막후도,구유량호적안전성。
Abstract?AlM:To investigate the clinical effect of intravitreal conbercept on wet age-related macular degeneration ( wAMD) and polypoidal choroidal vasculopathy ( PCV) .?METHODS:Sixteen patients (16 eyes) with wAMD and 5 patients ( 5 eyes ) with PCV, both clinical diagnosed, were enrolled. All patients were treated with intravitreous conbercept. Additional treatments were administered if needed. Best corrected visual acuity ( BCVA ) , central retinal thickness ( CRT ) and choroidal thickness ( CT) were measured periodically.?RESULTS:The mean injection times at 6mo was 2. 93 ± 0. 27. The mean BCVAs were 0. 87 ± 0. 52 at baseline and 0. 74 ± 0. 43 at 6mo, which the difference was not statistically significant. The mean CRT significantly improved from 352. 24±131. 82 to 251. 73±69. 41μm at 6mo (P<0. 01). The mean CT reduced from 331. 93±115. 35 to 304. 72±104. 59μm (P<0. 05).?CONCLUSlON: lntravitreal conbercept can keep the visual acuity stable, reduce the retinal thickness and is safe on treating wAMD and PCV.
